Wall Street brokerages predict that Regenxbio Inc (NASDAQ:RGNX) will post ($0.40) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Regenxbio’s earnings, with the lowest EPS estimate coming in at ($1.19) and the highest estimate coming in at $0.25. Regenxbio reported earnings of $0.04 per share in the same quarter last year, which would indicate a negative year over year growth rate of 1,100%. The company is expected to announce its next earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that Regenxbio will report full year earnings of ($2.15) per share for the current financial year, with EPS estimates ranging from ($3.06) to ($1.58). For the next year, analysts expect that the company will report earnings of ($1.30) per share, with EPS estimates ranging from ($2.13) to ($0.72). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Regenxbio.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.03). Regenxbio had a negative return on equity of 18.74% and a negative net margin of 99.57%. The business had revenue of $14.70 million during the quarter, compared to the consensus estimate of $7.46 million. During the same quarter in the prior year, the firm posted ($0.56) EPS. The company’s revenue for the quarter was up 177.0% on a year-over-year basis.
Shares of RGNX opened at $45.14 on Tuesday. The company’s fifty day moving average is $43.10 and its 200 day moving average is $40.36. Regenxbio has a fifty-two week low of $30.38 and a fifty-two week high of $63.21. The stock has a market capitalization of $1.72 billion, a PE ratio of -25.65 and a beta of 0.84. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.49 and a current ratio of 11.49.
In related news, Director Donald J. Hayden, Jr. sold 30,000 shares of the company’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $45.60, for a total value of $1,368,000.00. Following the completion of the sale, the director now directly owns 30,000 shares of the company’s stock, valued at $1,368,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Vittal Vasista sold 7,500 shares of the company’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $41.75, for a total transaction of $313,125.00. Following the completion of the sale, the chief financial officer now directly owns 232,215 shares of the company’s stock, valued at $9,694,976.25. The disclosure for this sale can be found here. Insiders have sold 49,016 shares of company stock valued at $2,256,957 over the last three months. Insiders own 13.80% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. IFP Advisors Inc lifted its stake in Regenxbio by 532.0% in the fourth quarter. IFP Advisors Inc now owns 1,264 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 1,064 shares during the period. NEXT Financial Group Inc raised its holdings in Regenxbio by 89.8% in the third quarter. NEXT Financial Group Inc now owns 2,566 shares of the biotechnology company’s stock worth $91,000 after purchasing an additional 1,214 shares in the last quarter. Royal Bank of Canada raised its holdings in Regenxbio by 36.2% in the second quarter. Royal Bank of Canada now owns 3,910 shares of the biotechnology company’s stock worth $201,000 after purchasing an additional 1,040 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its holdings in Regenxbio by 28.3% in the third quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 7,250 shares of the biotechnology company’s stock worth $258,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Sanders Morris Harris LLC bought a new position in Regenxbio in the fourth quarter worth about $300,000. 78.43% of the stock is owned by institutional investors.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.